Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7194-7203

  Sparano, Joseph A ^a   Goldstein, Lori J ^b   Childs, Barrett H ^c   Shak, Steven ^d   Brassard, Diana ^b   Badve, Sunil ^e   Baehner, Frederick L ^d   Bugarini, Roberto ^d   Rowley, Steve ^c   Perez, Edith A ^f   Shulman, Lawrence N ^g   Martino, Silvana ^h   Davidson, Nancy E ⁱ   Kenny, Paraic A ^a   Sledge Jr , George W ^e   Gray, Robert ^j  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Sanofi Aventis   (United States)

^d Genomic Health Inc   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h Angeles Clinic and Research Institute   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j Eastern Cooperative Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; RNA; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; AURKB GENE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CDC2 GENE; CHEK1 GENE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; EXPLORATORY RESEARCH; FOXM1 GENE; GENE; GENE EXPRESSION; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIFC GENE; MAJOR CLINICAL STUDY; PLK1 GENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; GENE EXPRESSION; GRB7 ADAPTOR PROTEIN; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 81255165016     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3357     Document Type: Article

References (45)

1. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer 2008;112: 737-47. (Pubitemid 351240567)
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
3. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44. (Pubitemid 352009225)
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
5. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23. (Pubitemid 36842560)
7. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71. (Pubitemid 43117611)
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74. (Pubitemid 39100473)
9. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008;8:363-9.
10. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008;26:2473-81.
11. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9.
12. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, et al. Prognostic utility of the 21-gene assay in hormone receptorpositive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-71.
13. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42. (Pubitemid 38364587)
14. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009;15:7693-700.
15. Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol; 28:4300-6.
16. Korn EL, Troendle JF, McShane LM, Simon R. Controlling the number of false discoveries: application to high-dimensional genomic data. J Statist Plan Infer 2004;124:379-98. (Pubitemid 38830084)
17. Korn EL, Li MC, McShane LM, Simon R. An investigation of two multivariate permutation methods for controlling the false discovery proportion. Stat Med 2007;26:4428-40. (Pubitemid 47534689)
18. Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Anal 2009;15:24-40.
19. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9. (Pubitemid 40260888)
20. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
21. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071-8. (Pubitemid 350182953)
22. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res;16:5351-61.
23. van deVijver MJ, HeYD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. Agene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
24. Badve SS, Baehner FL, Gray R, Childs B, Maddala T, Rowley S, et al. Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197. J Clin Oncol 25:18s, 2007 (suppl; abstr nr 21022).
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
26. Ramsey B, Bai T, Hanlon Newell A, Troxell M, Park B, Olson S, et al. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat;127:659-69.
27. Shen TL, Guan JL. Grb7 in intracellular signaling and its role in cell regulation. Front Biosci 2004;9:192-200.
28. Han DC, Shen TL, Guan JL. The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001;20:6315-21.
29. Manser J, Roonprapunt C, Margolis B. C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development. Dev Biol 1997;184:150-64. (Pubitemid 27225705)
30. Spector NL, XiaW, Burris H III, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12. (Pubitemid 47050840)
31. PeroSC, Shukla GS, CooksonMM,Flemer SJr, Krag DN.Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer 2007;96:1520-5. (Pubitemid 46762945)
32. Porter CJ, Wilce JA. NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein. Biopolymers 2007;88:174-81. (Pubitemid 46657983)
33. Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 2006;98:491-8.
34. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008;6:1795-806.
35. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003;4:722-31. (Pubitemid 36916714)
36. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88.
37. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8. (Pubitemid 46955132)
38. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7. (Pubitemid 38667616)
39. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
40. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15: 3094-102.
41. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66.
42. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 2009;4:e5592.
43. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 2009;28:742-51.
44. Dupuy A, Simon RM. Critical reviewof published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
45. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)